semaglutide and zepbound vs Zepbound outperforms Ozempic and Wegovy

However, brain endothelial cells actively interacting with other brain cells, including neurons, astrocytes, myocytes, pericytes, and extracellular matrix components (Muoio et al., 2014)

Natural levels of GLP-1 will be lower, meaning patients will feel hungrier and end up heavier than before

J Hum Reproductive Sci

Osteoarthritis: weight + pain In people with obesity and knee osteoarthritis , once-weekly semaglutide 2.4 mg produced: Greater weight loss Significantly larger reductions in knee pain Improved function Obstructive sleep apnea (OSA) The SURMOUNT-OSA phase 3 trials showed that tirzepatide (Zepbound) in adults with obesity and moderate-to-severe OSA: Reduced the apneahypopnea index (AHI) Lowered body weight, hypoxic burden, hsCRP, and systolic BP Improved sleep-related patient-reported outcomes compared with placebo In December 2024, the FDA approved Zepbound as the first medication specifically indicated for moderate-to-severe OSA in adults with obesity , alongside diet and physical activity

With the implicit validity of these data given the expected weight regain seen after therapy cessation, there is some credence to the idea that this is a genuine reflection of nondurability of weight loss with GLP-1 receptor agonist therapy

If you want a broader peptide overview before you pick one, start with peptide therapy